Why Realogy Holdings (RLGY) Stock Is Up Today

NEW YORK (TheStreet) -- Realogy Holdings (RLGY) was gaining 6.7% to $38.52 Monday after beating analysts' estimates for earnings and revenue in the second quarter.

For the second quarter Realogy Holdings reported earnings of 59 cents a share, beating the Capital IQ Consensus Estimate of 56 cents a share. Revenue grew 1.4% from the year-ago quarter to $1.51 billion, beating analysts' estimates of $1.49 billion for quarter.

"For the second quarter, we are pleased to report that we outperformed the high end of our previously announced guidance range by achieving homesale transaction volume gains of 3% for the quarter on a combined basis between our company-owned brokerages and franchise business segments," chairman, president, and CEO Richard A. Smith said in a press release. "While price was the principal reason for the overall volume increase, better-than-expected sides comparisons also drove the better-than-expected performance."

Must read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings team rates REALOGY HOLDINGS CORP as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:

"We rate REALOGY HOLDINGS CORP (RLGY) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself."

If you liked this article you might like

P&G's Director Problem Takes Center Stage in Battle With Activist Nelson Peltz

Zillow Sites Start Charging Fee for NYC Rental Listings, And One Big Broker Says No Thanks

A Famous Company You've Never Heard Of

Analysts' Actions -- Bristol-Myers, Merck, United Technologies and More

Bullish and Bearish Reversals for the Week